Jane Shaw retweeted
MRI in #Pleural Diseases!
Kevin Blyth @UofGMVLS @UofGlasgow will discuss on The Australasian Pleural Seminars 5/Aug 1pm AWST
Join us! Link in🧵#MedEd
@tsanz_thoracic @PleuralPOCUS @UKPleura @pleuralwales @NeumologiaHR @ALATorax @wabipconnect @APSRapsr
The most famous I will ever be: my hands on @YCGaryLee’s pleural pearls
#PLEURAL_PEARLS_WA 46
Clinicians always found it satisfying when pulled out pus from the chest tube... Pus results from degranulated leukocytes. #Pleural infection patients with pleural pus have better survival than those with non-purulent fluid. #MedEd
@PleuralPOCUS @TheRACP @RCPhysicians @AAB_IP @philchestorg @tsanz_thoracic @ALATorax @TheBMA @UKPleura @pleuralwales @EuroRespSoc @accpchest @APSRapsr @NeumologiaHR @AAB_IP @wabipconnect
Jane Shaw retweeted
Wonderful inaugural TAP Network Complex #Pleural Case Multidisciplinary Mtg
Professionally chaired: @kristiwithaB
Excellent panelists: @vin_george2; Grace Hennessy
Well organized: Cathy Read; @nc_huan
Great feedback from participants. We all learned.
Join next mtg Aug 28! #MedEd
@uwanews @tsanz_thoracic @Resp_Health @APSRapsr @AAB_IP @wabipconnect @BRONCHOLOGISTS @ALATorax @PleuralPOCUS @SMNYCT @accpchest @atscommunity @iPulmOG
Don't miss our 1st TAP Network on-line Complex #Pleural Case Mtg: May 27 10am Perth/HK/SG/MYS; 12 noon SYD/MELB; 2pm NZ. (Notice earlier start time). Link below #MedEd
@tsanz_thoracic @APSRapsr @BRONCHOLOGISTS @TOGAANZ @CancerCouncilOz @TheRACP @uwanews @PulmPEEPs @UKPleura @AAB_IP @wabipconnect @sfaiz212 @ARNS_UK @ALATorax
nature.com/articles/s41586-0… I love this. I love that people are thinking seriously about this, but mostly I just love the name.
Jane Shaw retweeted
🟩#TB pleural effusion: Diagnosis + Rx; a topic relevant to all pulmonologists/general physicians. @OnlyFreshAir will discuss on Feb 5 at THE AUSTRALASIAN #PLEURAL SEMINARS. Join us! @PleuralPOCUS @EuroRespSoc @AAB_IP @tsanz_thoracic @ARNS_UK @TBNTuberculosis @CDC_TB @PulmPEEPs
theconversation.com/the-peer… Some interesting things to consider. I have to agree that peer review does not always guarantee quality…
#MyOAarticle "Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology research" received 905 downloads since its publication. Access the article here: nature.com/articles/s41598-0…
This deserves many many reposts.
Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter! | American Journal of Respiratory and Critical Care Medicine atsjournals.org/doi/full/10.…
Jane Shaw retweeted
Clinical characteristics of chylothorax: results from the International Collaborative Effusion database openres.ersjournals.com/cont…
What a player
𝗥𝗲𝘁𝘀𝗵𝗲𝗴𝗼𝗳𝗮𝗱𝗶𝘁𝘀𝘄𝗲 '𝗢𝘅' 𝗡𝗰𝗵𝗲 🤯
Comes off the bench! 🪑
Dominates the scrum! 💯
Shakes the ref's hand while chaos ensues! 🤝
#RWC2023
Toddler's T cells are taught in muco-school | Science Immunology science.org/doi/full/10.1126…
Jane Shaw retweeted
Traditional cultures for diagnosing infection are limited by sensitivity & can require days to give results. The CHEST #Sepsis Resources Steering Committee outlines newer molecular methods that may be able to identify pathogens & drug resistance sooner: hubs.la/Q01YnMv10
Jane Shaw retweeted
Join us on Aug 2 for the Interventional Pulmonology Update Series Symposium! Presented by The Institute for Respiratory Health & Sir Charles Gairdner Hospital Interventional Bronchoscopy Unit. Don't miss out, READ MORE at wabip.com/events/601-lungvol…
Jane Shaw retweeted
Low airway surface pH impairs antimicrobial host defence and worsens airway inflammation. A novel, inhaled, alkaline buffer medication, Optate, raises airway pH and inhibits RSV infection in primary human airway epithelial cells in a dose-dependent manner. bit.ly/4138MAM
Jane Shaw retweeted
A mind-blowing paper has come out today in @Nature
In 2016, JC Venter Institute scientists trimmed a bacterial genome to its barest minimum required for life to synthesize what they called a "minimal genome" (science.org/doi/10.1126/scie…).
Today, a group of scientists from Indiana University reports how that minimal genome evolved over 2000 generations in comparison to the non-minimal genome.
The authors found that even when you reduce a bacterial genome to its absolute minimum where every nucleotide matters, the genome undergoes mutational events generation after generation as much as the non-minimal genome. One simply cannot stop the evolution.
Just over 300 days of evolution (equivalent to 40,000 years in humans) the minimal cell has gained everything it lacked in fitness on day one in comparison to the non-minimal cell.
When comparing the evolved traits between the minimal and non-minimal cells, the scientists found something striking. The evolutionary process increased the cell size of non-minimal cells but not that of the minimal cell. But that is not the striking part.
The scientists were able to identify the key mutation that resulted in cell size evolution. And it turned out that the mutation that helped the non-minimal cells to grow bigger is the same that helped the minimal cells to stay smaller. Growing bigger had a survival advantage for non-minimal cells and not growing bigger had a survival advantage for minimal cells. So, the mutation had a context-dependent effect. This just demonstrates that the evolutionary effects on traits have no absolute direction. All that matter is what is beneficial for the organism's survival.
The conclusion of the paper is metaphorically a quote from the Jurassic Park movie:
“Listen, if there’s one thing the history of evolution has taught us is that life will not be contained. Life breaks free. It expands to new territories, and it crashes through barriers painfully, maybe even dangerously, but . . . life finds a way". (scienmag.com/artificial-cell…)
nature.com/articles/s41586-0…
Well this is news to me
Online Now: Transcription factors interact with RNA to regulate genes dlvr.it/SrdGMP
We really need to be careful with bronchiectasis, we’re still learning.
The FORZA trial investigated beclomethasone–formoterol versus placebo in bronchiectasis without asthma or COPD. There were no signs of benefit and more adverse events, which warrants caution for the prescription of ICS/LABA therapy in bronchiectasis. bit.ly/3BMMUhX
Jane Shaw retweeted
1st in our Pleural Review Series #Semin #Respir Crit Care Med this month: 'Global Burden of Pleural Diseases' by @atrembla @NiloofaTg. Useful data to put magnitude to #pleural disease worldwide: excellent to cite for Intro section of any pleural work! #MedEd #MedTwitter @UKPleura
























